Pharmacotherapy of neurally mediated syncope

David G Benditt, Gerard J. Fahy, Keith G Lurie, Scott Sakaguchi, William Fabian, Nemer Samniah

Research output: Contribution to journalArticlepeer-review

83 Scopus citations


A wide variety of pharmacological agents are currently used for prevention of recurrent neurally mediated syncope, especially the vasovagal faint. None, however, have unequivocally proven long-term effectiveness based on adequate randomized clinical trials. At the present time, β-adrenergic receptor blockade, along with agents that increase central volume (eg, fludrocortisone, electrolyte-containing beverages), appear to be favored treatment options. The antiarrhythmic agent disopyramide and various serotonin reuptake blockers have also been reported to be beneficial. Finally, vasoconstrictor agents such as midodrine offer promise and remain the subject of clinical study. Ultimately, though, detailed study of the pathophysiology of these syncopal disorders and more aggressive pursuit of carefully designed placebo-controlled treatment studies are essential if pharmacological prevention of recurrent neurally mediated syncope is to be placed on a firm foundation.

Original languageEnglish (US)
Pages (from-to)1242-1248
Number of pages7
Issue number11
StatePublished - Sep 14 1999


  • Cardiovascular Drugs
  • Nervous system
  • Pharmacology
  • Syncope


Dive into the research topics of 'Pharmacotherapy of neurally mediated syncope'. Together they form a unique fingerprint.

Cite this